Hosted on MSN
COLL Q1 Earnings Call: ADHD Portfolio Drives Growth, Management Details Capital Deployment Priorities
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results , with sales up 22.7% year on year to $177.8 million. The company expects the full year’s revenue to be around ...
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – ...
STOUGHTON, Mass. and CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (COLL) and Corium Therapeutics Holdings, LLC (Corium Therapeutics), today announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results